Fiche société
Cabaletta Bio
Traitements, essais et publications liés.
Traitements5programmes
Essais3liés
Publications0liées
SourceDBlocale
Traitements
5| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| CABA-201RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis | Lupus, Myasthénie | Phase 1/2 | À vérifier | United States | À vérifier |
| CABA-201 following preconditioning with fludarabine and cyclophosphamideRESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy | Myopathies | Phase 2/3 | Immunomodulation | United States, United Kingdom | À vérifier |
| CABA-201RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis | Myasthénie | Phase 1/2 | À vérifier | United States | À vérifier |
| CABA-201RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis | Lupus | Phase 1/2 | À vérifier | United States, Canada, Spain | À vérifier |
| CABA-201 following preconditioning with fludarabine and cyclophosphamideRESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy | Myopathies | Phase 2/3 | Immunomodulation | United States, United Kingdom | À vérifier |
Essais cliniques
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| CABA-201 following preconditioning with fludarabine and cyclophosphamide | Myopathies | Phase 2/3 | NCT06154252 | RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy | RECRUITING |
| CABA-201 | Lupus | Phase 1/2 | NCT06121297 | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | RECRUITING |
| CABA-201 | Myasthénie | Phase 1/2 | NCT06359041 | RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||